Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

READY CMD LAMA2 is a Pre-Phase 1, single-arm, multicenter, prospective natural history clinical study to evaluate the natural history and potential early outcome measures in subjects with laminin α2-related dystrophy (LAMA2-RD) aged 0-5 years. The study seeks to enroll 44 subjects across 14 sites. NCH will enroll 10 subjects.

Subjects will complete in-person visits at Baseline, Month 6, Month 12, Month 18, and Month 24. Within two weeks of the Baseline, Month 12, and Month 24 visits, a remote visit will be performed to repeat and compare remote outcomes with in-person outcomes. Remote visits only will also be performed at Month 3 and Month 9. Adverse events will be captured every three months, beginning at baseline. Phone calls will be made by the coordinator and/or other delegated study staff at months 3, 9, 15, and 21.

The total study duration for each subject is up to 24 months.

Physical assessments to be performed will depend on the subject's age and may include the following:

• Assessment of motor milestones (maintained, lost or acquired)
• Neuromuscular Gross Motor Outcome (GRO)
• Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
• Motor Function Measure (MFM-20)
• Bayley-4
• Respiratory assessments: capnography and collection of data on use of non- invasive ventilation and other respiratory support
• Physical exam
• Swallow/oromotor assessment: To be performed by physician, occupational therapist, speech language pathologist, or other licensed professional at the site.
• Muscle ultrasound may be performed at some sites.

Other assessments:

• Growth parameters [head circumference, chest circumference, length, weight, body mass index (BMI)]
• 12-lead electrocardiogram
• Mode of feeding
• Peds Quality of Life (PedsQL) Neuromuscular Module
• Pediatric Evaluation of Disability Inventory (PEDI)
• Clinical Global Impression of Change (CGIC), physician and parent/caregiver assessed.
• Blood samples will be collected from subjects and stored for biomarker and other research purposes. Blood samples will be collected at each in-person visit.
• Data from electronic medical records of evaluations performed as standard of care visits will be collected.

Medical history, concomitant medications, and AEs will be collected and assessed for a potential relationship to participation in this study.

The total duration of the study for each subject is up to approximately 24 months. A subject will be considered to have competed the study if he/she has completed all assessments up to and including Month 24 assessments. The end of the study is defined as the date of completion of the last scheduled assessment shown in the Schedule of Events for the last subject in the study.

Subjects who prematurely discontinue study participation will be encouraged to complete an End-of- Study Visit to include assessment of motor milestones and recording of AEs.

Inclusion criteria

• Signed informed consent by the subject, parent(s) or legally authorized representative (LAR) and/or assent by the subject (when applicable).
• Subject must be aged birth to less than 5.0 years of age at time of consent.
• A confirmed diagnosis of LAMA2-RD confirmed via:

a: Two pathogenic variants in the LAMA2 gene (via a CLIA-approved laboratory) or: b. muscle biopsy with absence of merosin (laminin-211) and at least one pathogenic variant in the LAMA2 gene

• Absence of another confirmed genetic disease.
• Willingness to maintain current exercise and/or physical therapy regimen for the duration of the clinical study.
• Willingness to comply with the study protocol, including but not limited to, all study procedures and visits.

Exclusion criteria

• Acute medical illness or hospitalization within 30 days prior to informed consent.
• Participation in a previous trial of any investigational agent for LAMA2-RD within 1 month prior to informed consent, or use of any other investigational therapy (including off-label use of Losartan) within 30 days prior to informed consent, or participation in other clinical studies, within 30 days (or 3 half-lives, whichever is longer) prior to informed consent, which in the opinion of the PI, may potentially confound results from this study.
• Other significant medical condition, which in the opinion of the site Principal Investigator may confound interpretation of the clinical course of LAMA2- RD.